Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse... Annals of Hematology (2022) 101:2353–2354 https://doi.org/10.1007/s00277-022-04899-4 LE T TER TO  THE   EDITOR Eec ff tive treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B‑cell lymphoma leg type 1 2 1 Satoko Oka  · Kazuo Ono  · Masaharu Nohgawa Received: 9 May 2022 / Accepted: 13 June 2022 / Published online: 9 August 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 2 2 Dear Editor, (300  mg/m , day -6), etoposide (200  mg/m , days -5 to Primary cutaneous diffuse large B-cell lymphoma, leg -2), cytarabine (200 mg/m , days -5 to -2), and melphalan type (PCDLBCL-LT) is a rare and aggressive lymphoma. (140 mg/m , day -1), followed by the infusion of CD34 at The European Organization Society for Cutaneous Lympho- 1.8 × 10 /kg. The CR of lymphoma was confirmed in PET/ mas consensus recommendations indicate immunochemo- CT scans. One month later, relapse was detected at the therapy with R-CHOP as a first-line treatment [1 ]. Although original sites. With informed consent, ibrutinib (140 mg/ previous studies reported the significant clinical activity day) was initiated and the dose was increased up to 560 mg/ of lenalidomide or ibrutinib for PCDLBCL-LT, there are day. Marked improvements http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type

Annals of Hematology , Volume 101 (10) – Oct 1, 2022

Loading next page...
 
/lp/springer-journals/effective-treatment-with-polatuzumab-vedotin-of-relapsed-and-lJWg3Ouizr

References (7)

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/s00277-022-04899-4
Publisher site
See Article on Publisher Site

Abstract

Annals of Hematology (2022) 101:2353–2354 https://doi.org/10.1007/s00277-022-04899-4 LE T TER TO  THE   EDITOR Eec ff tive treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B‑cell lymphoma leg type 1 2 1 Satoko Oka  · Kazuo Ono  · Masaharu Nohgawa Received: 9 May 2022 / Accepted: 13 June 2022 / Published online: 9 August 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 2 2 Dear Editor, (300  mg/m , day -6), etoposide (200  mg/m , days -5 to Primary cutaneous diffuse large B-cell lymphoma, leg -2), cytarabine (200 mg/m , days -5 to -2), and melphalan type (PCDLBCL-LT) is a rare and aggressive lymphoma. (140 mg/m , day -1), followed by the infusion of CD34 at The European Organization Society for Cutaneous Lympho- 1.8 × 10 /kg. The CR of lymphoma was confirmed in PET/ mas consensus recommendations indicate immunochemo- CT scans. One month later, relapse was detected at the therapy with R-CHOP as a first-line treatment [1 ]. Although original sites. With informed consent, ibrutinib (140 mg/ previous studies reported the significant clinical activity day) was initiated and the dose was increased up to 560 mg/ of lenalidomide or ibrutinib for PCDLBCL-LT, there are day. Marked improvements

Journal

Annals of HematologySpringer Journals

Published: Oct 1, 2022

There are no references for this article.